It is very positive to witness the effect from our improved processes which not only benefits our customers, but also CS MEDICA's cash flow

We are proud to announce our presence in APAC (Asia Pacific) is growing with strong partners as this target region is one of the fastest growing within CBD and alternative OTC products. Furthermore, we are pleased that the European markets are actively requesting to distribute our branded products.

We at CS MEDICA are thrilled and proud to have achieved the distinction of being the first to introduce an OTC product with CBD to the Israeli market. This milestone is a testament to our commitment to developing innovative and effective Medical products under the CANNASEN® brand, and we look forward to bringing the full range of our CANNASEN® products to patients in Israel with the help of our partner, Forbe Healthcare.

Vitafoods Europe last year was a huge success and helped us grow our customer base and gain awareness of our CE-marked medical devices with CBD. We have expanded our presence to 15 markets the last year and expect to find more local partners to collaborate with in the coming days. Fortunately, this year we have again a product placed at Vitafoods Europe NEW PRODUCT section, our new Wound gel. Finally, we are proud to launch our new harmonized packaging design and reveal our upcoming launches on VET and SPORT segments at the booth.

By participating in a trade show, we aim to reach a wider audience, raise awareness of our brand, and connect with new customers. We additionally expect to generate leads by showcasing our products and attracting potential customers. Lastly, attending trade shows can provide valuable market insights, allowing us to keep up-to-date with industry trends and competitors.

We are thrilled with the positive results of this clinical trial, which further validates the efficacy and safety of Nasal Protect Gel in treating hay fever/allergic rhinitis.

We believe that Nasal Protect Gel has tremendous potential to improve the quality of life for millions of individuals suffering from chronic rhinitis, and we are excited about the future of this product in the market.

We are thrilled to introduce our CANNASEN products to the Indian market, which presents significant opportunities for our company. With the appointment of Kamlesh Vora as the Managing Director of CANNORDIC India Pvt Ltd, we have a seasoned leader who brings a wealth of experience to guide us through the complex regulatory landscape and successfully launch our products.

As the Managing Director of CS MEDICA's Indian subsidiary, I am thrilled to announce our expansion into the Indian market. With our expertise in MedTech and CBD-based medical devices, we are excited to bring our innovative products to India and provide safe and effective treatment options for patients suffering from autoimmune and stress-related disorders. Our commitment to combining science and nature aligns perfectly with the needs of the Indian market, and we are eager to submit our applications for registration with CDSCO[1]. We look forward to making a positive impact on healthcare in India and creating new opportunities for patients in need.

We are thrilled with the positive results of this clinical trial, which confirms the efficacy, safety, and tolerability of the CANNASEN® Pain Patch in managing pain. This is a significant milestone for our company, and it truly supports our go-to-market plans for our innovative and effective pain management solution.

Our successful, clinically proven, and documented results will help us speed up our go-to-market plans and begin taking market shares of a growing market. It also means we will look into a broader range of patches to match the demand for pain relief with CBD benefits.

With this JV agreement and business license in China we are stepping into a whole new area of the CS MEDICA. Together with RongShi we now have the necessary capacity in CS MEDICA to penetrate the Asian market with our CANNASEN®CBD medical products. I am truly looking forward to our cooperating with Mr. Gao (Jason), and with Guo Longlong (Harry), our Asian Director, who will be responsible for the Asian market. I am sure we together will reach new heights with the JV as well as for CS MEDICA

RongShi not only invests CS MEDICA in Denmark, but also setup “Rongshi Medica (Ordos) Co., Ltd.” in my hometown Erdos because I, my partner Mr. Xue and my team believe that the medical cannabis and CBD medical products will have a huge potential in the following 5 years in the market of China and other Asian countries. Today in China hemp growing cover more than 50% of the global production of Hemp, and many extraction companies produces CBD using CO2 extraction technology. These kinds of companies are located in Yunnan province and Heilongjiang Province, China. With the Joint Venture we differentiate from these hemp growers and extraction companies. We only focus on the CBD medical devices products approved by local FDA. This will reduce the risk for “Rongshi Medica (Ordos) Co., Ltd.” and CS MEDICA. We believe our cooperation will be success to reach the win-win

We believe that RongShi & CS MEDICA is a very good match, as RongShi provide funding, investment, local network & business knowledge in Asia, whereas CS MEDICA provides the technology, quality assurance & registrations. We look forward to our very first exhibition at the Global pharmaceutical exhibition CPHI in Tokoy Japan April 19 – 21, 2023, where Rongshi Medica (Ordos) Co., Ltd. Participate together with CS MEDICA.”

The negotiation with RongShi regarding an investment and Joint Venture in China has been a long and complicated process. Firstly, caused by our required share price with a premium of 454%, but also the cultural difference between Denmark & China and COVID-19 have had a huge impact. But as both parties had a true interest in this agreement, we finally found a solution acceptable for both parties.

We are so happy and proud of these agreements as this new funding of 60 MDKK, is the most important agreement CS MEDICA has made, and this without any expensive financial advisors involved, meaning the total funding is received by CS MEDICA. Mr. Guo (Harry), Asian Director in CS MEDICA has been involved in the process from the very beginning and have been a great help for CS MEDICA recognizing and handling the culture difference and importance of the face-to-face meeting doing the business with Chinese company. This is why we decided to visit RongShi Hi-Tech Co. Ltd in March after the failed negotiation in January. Now CS MEDICA has succeeded entering into a final agreement with Inner Mongolia RongShi Hi-Tech Co., Ltd regarding a total equity investment of DKK 60M in CS MEDICA at a share price of DKK 28.13

CS MEDICA and RongShi have 100% confidence to receive the registration approval from China National Medical Products Administration within 3 months if classified as Class I Medical Device. If classified as Class II Medical Device, we will receive the registration approval within 12 months. Even the worst scenario is we can’t receive the registration approval within 12 months from China National Medical Products Administration. Our JV will produce our brand products CANNASEN® CBD in our JV production line and apply for the registration approval from the Inner Mongolia Medical Products Administration. This will be easy to receive the registration approval because JV is a domestic company to the Inner Mongolia government and Inner Mongolia Medical Products Administration.

We chose to contact CS Medica as we see great advantages in being a First-Mover into the Asian market and the natural synergies between their medical technology platform and our production capacity and distribution network. We have recently noticed that the market in Asia has matured and is now ready for CBD-products, and we are at the end of our Due Diligence and looking forward to taking further steps ahead. Our ambition is to be a strong long-term partner.

I really look forward to discussing the process and joint venture further with Rong Shi when they visit us later the year.

"We are happy to announce that CS MEDICA is closing the year with 10,6M DKK in revenue, and we are proud of the strong partnerships we have developed in the last months. We have moved from being an R&D to a commercialized company, now listed in most pharmacies in DK, on Amazon, and we have signed with distributors in Israel, Hong Kong, Slovenia, Croatia, and Serbia to market our Cannasen® brand. The latest distribution partner we have teamed up with is Alliance Healthcare Romania, part of the Alliance Healthcare, one of the largest wholesalers in Europe, supplying more than 115,000 pharmacies, doctors, and health centers in 13 countries. This order includes our full Cannasen® portfolio incl. the new Wound Gel." 

We are happy to have this huge investment interest from the Asian market, and Inner Mongolia Rong Shi Hi-Tech Co. as well as us are aiming for a quick due diligence as we hope to get into operation as soon as possible

CS MEDICA are happy to announce that we found a strong partner, with the right strategy in place, to kick start sales in several Balkan countries. We see this as an opportunity to step into a region, not easily accessible without the know-how in the market. Also, this as an option to further develop the Balkan and Eastern EU presence in near future.

Ampilio has done a great job helping us launch on both the Swedish and German Amazon; however, we experience products containing CBD need a different strategy and communication. The speed to market has been too slow; consequently, we agreed to move our partnership to Incubeta Maze-One, a preferred Amazon partner like Ampilio, but who is familiar working with CBD brands on Amazon.

We work with several Nordic brands within personal care, including CBD-based products, where we see an increasing sales potential in Europe. Selling CBD-based products on Amazon comes with certain compliance demands that require special solutions and communication tactics. We look forward to working with CS MEDICA to build and grow Amazon as a sales channel.

We are looking forward to starting the process preparing the CS MEDICA’s shares to the Main Market in Denmark.

We are happy we launched at Spotlight as a nano/microcap company in an early growth phase, and the support has been outstanding. However, as we have finalized the main clinical trials, we are rapidly reaching international territories with our finished, registered products plus the technology and science behind the formulas and CBD know-how, allowing us to reach further segments. Combined with the fact we have a first mover advantage, being ahead of the competition on registrations from MDD to MDR, we need to capitalize now. Hence, we need to prepare for the next growth phase, and have been recommended to start the process of moving to the Main Market

Alsitan has had a very successful market reception of the arthritis gel in the German market and is now expanding their portfolio with another white label CANNASEN product - a new advanced arthritis pain gel. Together with Alsitan, who are experts in their field, this order gives us a unique opportunity to better match our product portfolio to the market dynamics. We see this not only as proof of concept, but also proof of business.

he registration at the MHRA in the UK is an important step for CS MEDICA as the UK works as a display market for Australia, MENA (Middle East and North Africa) and other countries where the local health authorities use the UK as a reference country. Hence the MHRA registration is an significant mark in our efforts to create global awareness and sale

We are very pleased with the successful warrant exercise. We welcome all new and existing shareholders on our continued journey ahead.

We are proud to announce, that we finally made it to the pharmacies, with agreement signed with two of the three leading pharmacy chains in Denmark. We will use and optimize this new position in the market by accelerating our listings and built brand stores on the growing players within the online pharmacy channel.

We are very proud to be able to become the first legal CBD brand to enter the Israeli market, notably as Israel is one of the global leaders within the area of CBD and Cannabis research. We look very much forward to our collaboration with our strong partner in Israel, Forbe HealthCare Ltd., and we are confident that we together will develop a strong success story in the Israeli market.

I am very pleased to announce that CS MEDICA has expanded their product portfolio now also covering protection against COVID-19 virus infection. This opens a new market for the Company which has a huge market potential with the fall being just around the corner and thereby also a season for COVID-19.

We strongly believe in CS MEDICA’s bright future and by extending our lock-up agreement it reconfirms our commitments to the future development of the Company and we have no intention of selling our shares now

One of the things to secure when building a global business is trademarks. CS Medica has always been active in filing patents to secure the future for our products, but we also see the value of securing our brands with trademark registration. This is an additional important step we are taking in our global sales strategy.

This clinical study results, mark another important step for CS MEDICA and continues our strong track record for delivering impactful products. It gives us a unique position in the market as first mover with proven effective and safe Medical CBD products. It paves the way for further R&D of products within this category and gives us a solid foundation to build our commercial track record. These results combined with the patents pending and trademark foresee a high value & revenue in the years to come. We are proud to share these results as the trial shows that the CANNASEN®CBD Arthritis Gel & CANNASEN®CBD ARTH Supplement in combination are proving to be both safe and efficient for patients and most important our CANNASEN®CBD Arthritis Gel & CANNASEN®CBD ARTH Supplement improves the overall quality of life for patients with Osteoarthritis.

We are glad to see that our hard efforts are paying off with the further expansion of our sales channels and that we are now also represented in Germany by Amazon. We see that this is a growing market with great potential.

I am very glad to announce that CS MEDICA continues to expand on the European market. The Agreement with NaturaMedica demonstrates that our products are wanted and gives us a broader customer base in Europe. We hope that this agreement will spark more interest around Europe as we continue our expansion.

We are proud to announce that we have signed our first agreement that covers both the market in Israel and Palestine. For CS MEDICA, the signing of this agreement demonstrates the capabilities of our products and will be a key part of helping us reaching our financial goals in the years to come. I am proud that we continue to break ground on the global market and that our expansion is continuing.

The clinical study results mark an important step for CS MEDICA as we continue our strong track record for delivering impactful products. We are proud to share these results as the trial shows that the CANNASEN®CBD Arthritis Gel is proving to be both safe and efficient for patients and most important our CANNASEN®CBD Arthritis Gel improves the overall quality of life for patients with osteoarthritis.

We were proud to be selected to showcase our unique and innovative products at the Vitafoods event. We feel that our products were highlighted especially as our products represented the only medical device brand with products containing CBD. We engaged in several interesting discussions and we found our participation very productive, especially with the global presence of different partners.

Our previous white label order received from Alsitan, a total of 40,000 units of the Arthritis gel had a very successful market reception at the German market and is now sold out. Following the successful market launch we have now entered into a private label agreement with Alsitan, covering the German and Austria territory. The agreement, covering the Arthritis gel launched under the brand name “Alsiroyal”, is based on minimum orders, in year 1 and 2, of 40,000 units and in 2024 at 60,000 units. The agreement automatically continues beyond the 3 years, after which new minimum orders are to be set.”

We are very proud of finally breaking ground in a bigger scale. With our agreement with, Chinese based CBF SciTech Ltd, we now lift our business to a new level. We are now beginning to reap the reward of all our efforts, and I strongly believe that this is only the beginning.

I am happy to welcome Heidi Ahlefeldt-Laurvig as CGO/CMO. Heidi has extensive experience in marketing and digitalization and possesses a rare toolbox encompassing a complete set of skills corresponding to our ambitions. With Heidi's expertise, I am confident that she will be an important asset in our continued growth journey.

The validation of CANNASEN® being officially confirmed as a trademark in the US is of key importance for our strategy going forward in the North American market.”

Although we are not in need of the funding coming from the DIAZ Direct issue, we saw an opportunity that we could not overpass. With the agreements, with and cooperation network of DIAZ altogether focusing on future growth, and the kick start of our Investor Relation area, we secure a more thorough understanding of the company and the possibilities within the business area of CS MEDICA.

The strategy to build strong customer relationships drive sales, sustainability, and growth, this is something we see that the SpectrumOne group has delivered for their clients’ time and time again so our choice to work with them couldn’t have been easier, we have one of the best revolutionary CBD medical products on the market and with Ampilios help they will deliver this message to the world market and create lifelong relationships with our customers.

For a company providing pharmaceutical products containing cannabis and cannabinoids, this initiative is very satisfactory as it 'eases' the regulatory situation and shows a form of market acceptance. We hope that Germany will mark the starting point for further legislation processes in Europe. These legislations are of great importance and can have potential effects on the operations of CS MEDICA. The effects are not only connected to the market growth of our current product portfolio but also the upcoming dispenser product line. Legislations like these symbolize a sense of acceptance for our industry and we are glad that the market trends are moving in the right direction.

We are glad that the Danish Parliament has expressed their support for the cannabis industry in Denmark. This regulation reflects positively on our business as these regulatory reforms will increase the awareness of medical cannabis and hopefully allow the industry to grow even more. We feel confident that this news will have a positive impact on the industry and market in which we operate while also decreasing a risk factor for our company.

We are experiencing great interest in our product portfolio. However, following the clinical delays in India, we are delayed in negotiations with a potential customer. We expect to finalize the agreement in 2022. However, as a result, we will not achieve our financial target for the fiscal year 2020/2021. Instead, the expected agreement will have a positive impact on the results for 2021/2022. We see no reason to revise our future objectives”, comments Lone Henriksen, CEO of CS MEDICA.

As this is our first order by a private label customer, we are very excited. This agreement signifies the potential for further advances in the private label field and further follows our communicated financial expectations for our business.